EP300 and diffuse large B-cell lymphoma: BCL6 activity is also impaired by another set of genetic mutations affecting the post-transcriptional regulatory mechanism of CREBBP/EP300, which impairs the acetylation-mediated BCL6 inactivation and FBXO11 mutations that occurs in 5% of DLBCL cases [88].